



COVID-19 Update

from the Tennessee Department of Health

TN

Mary-Margaret A. Fill, MD
Deputy State Epidemiologist
Tennessee Department of Health
April 9, 2021

Critical Indicators

GUIDELINES

OPENING UP AMERICA AGAIN



Proposed State or Regional Gating Criteria

(Satisfy Before Proceeding to Phased Opening)

SYMPTOMS

Downward trajectory of influenza-like illnesses (ILI) reported within a 14-day period

AND

Downward trajectory of COVID-like syndromic cases reported within a 14-day period

CASES

Downward trajectory of documented cases within a 14-day period

OR

Downward trajectory of positive tests as a percent of total tests within a 14-day period (flat or increasing volume of tests)

HOSPITALS

Treat all patients without crisis care

AND

Robust testing program in place for at-risk healthcare workers, including emerging antibody testing

Syndromic Surveillance

- **Emergency department data**
 - Chief complaints
 - Discharge diagnoses
- **Deidentified**
- **Received within 24h of patient encounter**
- **Reported from 99 hospitals across TN**
- **Syndromes**
 - **Influenza-like illnesses (ILI)** is defined by terms, free text, or discharge diagnoses that are likely to be related to illness caused by seasonal influenza. The visits counted within these criteria will contain a percentage illnesses caused by conditions other than influenza infection. These results should be considered preliminary in nature and are not all confirmed diagnoses of disease.
 - **COVID-like illnesses (CLI):** is defined as symptom terms, free text, or discharge diagnoses specified by CDC that are likely to be related to illness caused by the 2019 novel Coronavirus. The visits counted within these criteria will contain a percentage illnesses caused by conditions other than novel coronavirus infection. The visits counted within these criteria will contain a percentage illnesses caused by conditions other than novel corona virus infection. These results should be considered preliminary in nature and are not all confirmed diagnoses of disease.


SYMPTOMS

Downward trajectory of influenza-like illnesses (ILI) reported within a 14-day period

AND

Downward trajectory of COVID-like syndromic cases reported within a 14-day period


Syndromic Surveillance



Case Counts (Weekly)

By Specimen Collection Date

820,965
Total Cases




CASES

Downward trajectory of documented cases within a 14-day period


OR

Downward trajectory of positive tests as a percent of total tests within a 14-day period (flat or increasing volume of tests)


7d Average of New PCR Tests (n=7,331,235)



PCR Test Percent Positivity



Antigen Testing Data (n=1,686,333)



Deaths (n=11,997)

Case Fatality
Rate:


1.5 %

(11,967/818,008)

30-Day Case
Fatality Rate:

1.2 %

(356/30,078)



Healthcare Resources


- **Healthcare Resource Tracking System**
 - Established in 2006
- **Acute care hospitals report daily:**
 - Number of beds (floor / ICU / AIIR)
 - Number of ventilators
 - Amount of PPE
 - Number of COVID-19 patients (floor, ICU, ventilated, pending)

HOSPITALS

Treat all patients without crisis care


AND

Robust testing program in place for at-risk healthcare workers, including emerging antibody testing



Current COVID Hospitalizations


COVID patients represent ~7% of all hospitalized patients in TN.



Effective Primary Prevention Measures

THE SWISS CHEESE RESPIRATORY VIRUS PANDEMIC DEFENCE

RECOGNISING THAT NO SINGLE INTERVENTION IS PERFECT AT PREVENTING SPREAD



EACH INTERVENTION (LAYER) HAS IMPERFECTIONS (HOLES).
MULTIPLE LAYERS IMPROVE SUCCESS.

IAN M MACKAY
VIOLOGYDOWNUNDER.COM
WITH THANKS TO JODY LANARD, KATHERINE ARDEN & THE UNI OF QLD
BASED ON THE SWISS CHEESE MODEL OF ACCIDENT CAUSATION, BY JAMES T REASON, 1990
VERSION 3.0
UPDATE: 24OCT2020

COVID-19 Vaccine



COVID-19 Vaccines

3

Three vaccines currently have an emergency use authorization from FDA

- Pfizer, Moderna, Janssen (J&J)

3

Three more vaccines will likely have emergency use authorization from FDA in 2021.

5

Five of these six vaccines require two doses

- Both doses must be from the same manufacturer











COVID Vaccines Are Effective

COVID vaccines are 100% effective at preventing COVID hospitalization and COVID death

Vaccine trial	Approximate # of people who received the vaccine	Of people vaccinated in the trial		
		# hospitalized for COVID	# who died from COVID	# who died from the vaccine
Moderna	15,000	0	0	0
Pfizer	18,600	0	0	0
Novavax*	13,000	0	0	0
Astra-Zeneca	5,800	0	0	0
J&J*	22,000	0	0	0

CDC Post-Vaccination Recommendations

Activity	
Visit inside a home or private setting without a mask with other fully vaccinated people of any age	
Visit inside a home or private setting without a mask with one household of unvaccinated people who are not at risk for severe illness	
Travel domestically without a pre- or post-travel test	
Travel domestically without quarantining after travel	
Travel internationally without a pre-travel test depending on destination	
Travel internationally without quarantining after travel	
Visit indoors, without a mask, with people at increased risk for severe illness from COVID-19	
Attend medium or large gatherings	

Vaccine Allocation Phases

■ Age-Based



■ Risk-Based



Refer to age-based criteria for all other industries and general population.

Estimated timeline and phases are preliminary and subject to change.

Vaccine Allocation Phases: As of April 5th

All Tennesseans 16+ Eligible for Vaccine

1.8 Million+ Tennesseans Vaccinated

[FIND AN APPOINTMENT](#)

TN Vaccination Rollout

- 4,336,225 doses delivered
- 3,114,335 (72%) administered as of 4/8/21
- 29.2% of people statewide have received at least one dose

Number of People with
Series Initiation (1 dose of Pfizer / Moderna)
Series Completion (2 doses of Pfizer / Moderna
OR 1 dose of Janssen)

805,712

1,187,706

Total Doses Delivered				
Site Type	Manufacturer	Doses Delivered	1st Doses Allocated	Total Doses Allocated
Other Providers	Janssen	263,500		
	Moderna	1,913,100		
	Pfizer	2,159,625		
LTCF Pharmacy Partnership	Moderna		75,700	151,400
Total		4,336,225	75,700	151,400

TN Vaccination Rollout

Age Group

People Vaccinated % of People Vaccinated

16-20 years	42,918	2.2
21-30 years	173,389	8.7
31-40 years	224,867	11.3
41-50 years	255,444	12.8
51-60 years	342,254	17.2
61-70 years	445,450	22.3
71-80 years	353,169	17.7
81+ years	156,766	7.9
Pending	251	0.0
Total	1,994,508	100.0

Patient Ethnicity

People Vaccinated % of People Vaccinated

Hispanic or Latino	65,638	3.0
Not Hispanic or Latino	1,668,707	83.9
Unknown	260,163	13.2
Total	1,994,508	100.0

Patient Race

People Vaccinated % of People Vaccinated

Asian	38,217	1.7
Black or African American	211,808	10.2
White	1,373,546	69.7
Other/Multiracial	231,531	11.3
Unknown	139,406	7.1
Total	1,994,508	100.0

Patient Sex


People Vaccinated % of People Vaccinated

Female	1,138,250	57.1
Male	850,894	42.7
Other	547	0.0
Unknown	4,817	0.2
Total	1,994,508	100.0

TN Vaccination Rollout (<https://vaccinefinder.org>)

Vaccine allocations to:

- Local health departments
- Hospitals
- Community Health Centers
- Federally Qualified Health Centers
- Independent pharmacies
- Chain pharmacies
- Large private medical groups
- Smaller medical groups



COVID19.TN.Gov


- Vaccine Location Map
- Vaccine Eligibility Tool
- Vaccine Phases County Map
- COVID-19 County Dashboards
- Symptoms Checker
- Quarantine/Isolation Calculator
- Shareable Content (blogs, videos, images)



Getting Vaccinated: <https://covid19.tn.gov>



RISK-BASED PHASE BY COUNTY

AGE-BASED PHASE BY COUNTY



HEALTH DEPT. VACCINE AVAILABILITY

Following Progress: <https://covid19.tn.gov>



<https://covid.cdc.gov/covid-data-tracker/#vaccinations>

Questions?

©Dan Holland



Mary-Margaret A. Fill, MD
Email: Mary-Margaret.Fill@tn.gov
Work: (615) 532-6752